title: A new prognostic score based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer.
abstract: OBJECTIVE
  Pretreatment systemic inflammatory response has been confirmed to have prognostic value in patients with inoperable non-small-cell lung cancer (NSCLC). Increasing studies show that the modified Glasgow prognostic score (mGPS), a prognostic score based on C-reactive protein (CRP) and albumin, is a prognostic factor in these patients. This study was aimed at recognizing possible prognostic factors and new prognostic scores of inoperable NSCLC based on pretreatment systemic inflammatory response.
  
  
  METHODS
  We retrospectively reviewed the clinicopathological data of 105 patients with inoperable NSCLC who received first-line chemotherapy as initial treatment. Univariate and multivariate analyses of progression-free survival (PFS) and overall survival (OS) for prognostic factors and scores were performed.
  
  
  RESULTS
  The serum CRP, lactate dehydrogenase (LDH), cancer antigen 125 (CA125), and pathological type were independent pretreatment prognostic factors for PFS and OS. A new score was assembled by CRP, LDH, and CA125. In multivariate analysis, when the mGPS and the new score were covariates, only the new score retained independent prognostic value for both PFS (P<0.001; hazard ratio =2.12; 95% confidence interval: 1.60-2.82) and OS (P<0.001; hazard ratio =1.82; 95% confidence interval: 1.33-2.48).
  
  
  CONCLUSIONS
  The new score based on pretreatment serum level of CRP, LDH, and CA125, indicates the prognosis of both PFS and OS in patients with inoperable NSCLC who were treated with first-line systemic chemotherapy, and it was found to be more effective than mGPS.
authors.affiliation: Department of Medical Oncology, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, People's Republic of China.
authors.forename: Lizhen
authors.initials: L
authors.lastname: Zhu
authors.affiliation: Department of Medical Oncology, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, People's Republic of China.
authors.forename: Xiaofen
authors.initials: X
authors.lastname: Li
authors.affiliation: Department of Medical Oncology, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, People's Republic of China.
authors.forename: Yanwei
authors.initials: Y
authors.lastname: Shen
authors.affiliation: Department of Medical Oncology, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, People's Republic of China.
authors.forename: Ying
authors.initials: Y
authors.lastname: Cao
authors.affiliation: Department of Medical Oncology, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, People's Republic of China.
authors.forename: Xuefeng
authors.initials: X
authors.lastname: Fang
authors.affiliation: Department of Medical Oncology, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, People's Republic of China.
authors.forename: Jiaqi
authors.initials: J
authors.lastname: Chen
authors.affiliation: Department of Medical Oncology, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, People's Republic of China; Cancer Institute, Key Laboratory of Cancer Prevention and Intervention, Chinese National Ministry of Education, Hangzhou, Zhejiang Province, People's Republic of China.
authors.forename: Ying
authors.initials: Y
authors.lastname: Yuan
keywords: C-reactive protein; CA125 antigen; lactate dehydrogenase; prognostic score